BioCryst Pharmaceuticals | BCRX - 税前利润



金融业
股票价格
USD
资产
USD 514.16M
现金及等价物
USD 335.91M
销售成本
USD 9.52M
流动资产
USD 404.35M
流动负债
USD 196.07M
债务
USD 828.6M
股息收益率
0
EBIT
USD 260.39M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 1.17
股本和储备
USD -119.15M
销售毛利
USD 153.05M
债务利息支出
USD 14.14M
利息收入
USD -0.13
贷款资金
USD 428.67M
市值
USD 2.05B
净收入
USD 245.85M
营业费用
USD 146.17M
营业利润
USD 260.39M
普通股股本
USD 213.06M
PE价格收益
6.06
税前利润
USD 248.02M
销售收入
USD 406.56M
销售和管理费用
USD 95.78M
股票
USD 5.4M
贸易债权人
USD 15.83M
应收帐款人
USD 106.82M


税前利润 更改 日
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Chugai Pharma JPY 169.9B 13.83B 2025-12
Daiichi Sankyo JPY 106.73B 48.96B 2025-12
DBV Technologies USD -33.16M 8.6M 2025-09
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Gilead Sciences USD 3.64B 1.21B 2025-09
GlaxoSmithKline GBP 1.23B 1.23B 2025-12
Glaxosmithkline GBP 2.46B 569M 2025-09
Incyte USD 389.94M 92.37M 2025-12
Ionis Pharmaceuticals USD -228M 99M 2025-12
Karyopharm Therapeutics USD -30.89M 1.16M 2024-12
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Novavax USD 17.9M 220.94M 2025-12
PTC Therapeutics USD -139.08M 116.01M 2025-12
Regeneron Pharmaceuticals USD 1.76B 244.6M 2025-09
Roche Holding CHF 4.79B 3.01B 2025-06
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
Ultragenyx Pharmaceutical USD -128M 51.54M 2025-12
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09